The University of Kansas Cancer Center

01/24/2026

Extreme winter weather is about to impact the Kansas City metro. Our physician in chief, Dr. Jeffrey Holzbeierlein, has a message for patients: your safety comes first.

01/23/2026

Testing for certain features in cancer (called biomarkers) can tell doctors about what’s causing the cancer to grow. The study is for adults just diagnosed with acute ( ) or syndrome ( ). It uses advanced biomarker testing to try to match patients with a myeloMATCH clinical trial for cancer treatment. Ask your doctor to learn more. You can also call 1-800-4-CANCER or visit https://swog.org/myeloMATCH

01/21/2026

Researchers at The University of Kansas Cancer Center have received a new grant from Tina's Wish - The Honorable Tina Brozman Foundation for Ovarian Cancer to support innovative work focused on detecting ovarian cancer at earlier, more treatable stages. This research aims to improve screening approaches and deepen our understanding of how ovarian cancer develops, helping move the field closer to earlier diagnosis and better outcomes for patients. Learn more about this research and the impact of the grant ➜

Tina’s Wish has awarded a Team Science Grant to Andrew Godwin, PhD, deputy director of The University of Kansas Cancer Center, and Steven Soper, PhD, Foundation Distinguished Professor in the departments of Chemistry and Mechanical Engineering at the University of Kansas.

01/20/2026

Do you know a college student that is interested in a career in clinical research? Applications are open for the 2026 summer session of the CAREERS in Clinical Research Program (C-CLEAR Program) at The University of Kansas Cancer Center! The groundbreaking initiative introduces college students to the impactful and often-overlooked field of clinical research. The eight-week program allows interns hands-on experience to all aspects involved in clinical research. Learn more about the C-CLEAR Program and how to apply at https://bit.ly/4hyoqft.

01/19/2026

Today we celebrate Martin Luther King Jr.'s timeless values, leadership and empowerment.

01/18/2026

In recognition of the upcoming Martin Luther King Jr. Day holiday, some of The University of Kansas Cancer Center’s offices will have modified hours on Monday, January 19. Learn more: https://bit.ly/4qP7824

01/17/2026

In 2018, then 29-year-old Austin Hill, father of 3, was diagnosed with an aggressive form of stage IV stomach cancer. Despite quick action including surgery to remove the cancer and HIPEC, a procedure that involves filling the abdomen with heated chemotherapy drugs, the cancer remained. That wasn’t the end of Austin’s story. His cancer team found he qualified for immunotherapy. A treatment that used his own body’s immune system to target the cancer. Learn more. https://bit.ly/3Zbx5gq

01/17/2026

In recognition of the upcoming Martin Luther King Jr. Day holiday, some of The University of Kansas Health System’s offices will have modified hours on Monday, January 19. Learn more. ➡️https://bit.ly/4sK20hB

01/16/2026

Surviving childhood cancer is not the finish line, it’s the beginning of a lifelong journey.🎗️

Research shows that more than 99% of childhood cancer survivors face a chronic health condition, and 96% experience a severe or life-threatening complication related to their treatment by the age of 50. That is why survivorship is a core pillar of the research we fund at Braden's Hope For Childhood Cancer.

We recently announced our Super Six Research Grant recipients and we are excited to shine a light on each study. We proudly funded an impactful project led by Dr. Carolyn Bates and Dr. Kari Struemph at The University of Kansas Cancer Center.

This initiative is designed to support childhood cancer survivors as they transition from pediatric to adult health care - a critical and often overwhelming phase where too many young people fall through the cracks. This research is an investment in helping survivors not only live beyond diagnosis, but thrive well into adulthood because we know the fight doesn’t end when treatment does.🎗️

Stay tuned for exciting updates on their research.

01/15/2026

The University of Kansas Cancer Center has been named among the initial certified treatment centers for Aucatzyl, a new CAR T-cell therapy. Aucatzyl is used to treat acute lymphoblastic leukemia in adults. It is the seventh FDA-approved CAR T-cell therapy. The cancer center is the only location in our region to offer all 7 available CAR T-cell therapies. Learn more: https://bit.ly/3Ec010t

01/14/2026

Pancreatic cancer is one of the most challenging cancers to treat. This January, we recognize Pancreatic Cancer Clinical Trials Awareness Month and the critical role research plays in advancing care.

Clinical trials may offer opportunities to explore new approaches to prevention, diagnosis and treatment.

Learn more about pancreatic cancer clinical trials at The University of Kansas Cancer Center ➜ https://bit.ly/49EcfLG

01/14/2026

Proton therapy is particularly beneficial for treating children and adolescents with cancerous and noncancerous tumors. Children are at a significantly higher risk of late effects from cancer treatments compared to adults. Two-thirds of children who survive a cancer diagnosis face at least one chronic health condition. One-fourth of pediatric cancer survivors face a severe or life-threatening side effect from treatment that occurs later in life. These include heart damage, lung damage, infertility, cognitive impairment, growth deficits, hearing loss, vision loss, secondary cancers and more.

Thanks to treatment advances, including radiation, pediatric cancer survival rates have dramatically increased to nearly 85% today from 10% only decades ago. One of these advancements, proton therapy, reduces a child’s risk of experiencing harmful long-term side effects. Proton therapy limits and reduces radiation doses to healthy tissues and organs while delivering curative doses to the cancer. Learn about proton therapy: https://bit.ly/3K37IEe